Product Description
Organicell Regenerative Medicine is developing Zofin as a treatment for COVID-19, COPD, and Osteoarthritis. (Sourced from: https://organicell.com/zofin-2/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Pakistan
Approved Indications: None
Known Adverse Events: None
Company: Organicell Regenerative Medicine
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Acute Lung Injury|Acute Respiratory Distress Syndrome|COVID-19|Respiratory Distress Syndrome, Newborn
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05228899 | P2 |
Completed |
COVID-19 |
2023-10-01 |
25% |
| NCT04384445 | P2 |
Completed |
COVID-19|Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn|Acute Lung Injury |
2023-07-01 |
35% |